Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

被引：76
|
作者：
Praveen, D. [1 ]
Puvvada, Ranadheer Chowdary [1 ]
Aanandhi, Vijey M. [2 ]
机构：
[1] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Chennai 600117, Tamil Nadu, India
[2] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Dept Pharmaceut Chem & Anal, Chennai, Tamil Nadu, India
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2020年 / 55卷 / 05期
关键词：
SARS-CoV-2; COVID; 19; Baricitinib; Novel Corona Virus;
D O I：
10.1016/j.ijantimicag.2020.105967
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
    Florescu, Diana F.
    Kalil, Andre C.
    CURRENT OPINION IN CRITICAL CARE, 2021, 27 (05) : 493 - 496
  • [22] An EUA for Baricitinib (Olumiant) for COVID-19
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1614): : 202 - 203
  • [23] Baricitinib for COVID-19: a suitable treatment?
    Favalli, Ennio G.
    Biggioggero, Martina
    Maioli, Gabriella
    Caporali, Roberto
    LANCET INFECTIOUS DISEASES, 2020, 20 (09): : 1012 - 1013
  • [24] Baricitinib: A chance to treat COVID-19?
    Lo Caputo, Sergio
    Corso, Gaetano
    Clerici, Mario
    Santantonio, Teresa Antonia
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2343 - 2344
  • [25] COVID-19: Baricitinib in inpatient Therapy
    Meinrenken, Susanne
    PNEUMOLOGIE, 2021, 75 (05): : 329 - 329
  • [26] Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib
    Fischer, Kristina
    Aringer, Martin
    Steininger, Julian
    Heil, Julius
    Beissert, Stefan
    Abraham, Susanne
    Gunther, Claudia
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : 432 - 435
  • [27] DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
    Sonia, Chiging
    Devi, Th. Gomti
    Karlo, T.
    MATERIALS TODAY-PROCEEDINGS, 2022, 65 : 2586 - 2595
  • [28] Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis
    Karaa, S.
    Cassius, C.
    Jachiet, M.
    Mahevas, T.
    Charvet, E.
    Benveniste, O.
    Bouaziz, J. -D.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2023, 150 (03): : 243 - 245
  • [29] Janus Kinase inhibitor Baricitinib Modulates human innate and adaptive immune system
    Kubo, Satoshi
    Nakayamada, Shingo
    Sakata, Kei
    Kitanaga, Yukihiro
    Ma, Xiaoxue
    Lee, Seunghyun
    Ishii, Akina
    Yamagata, Kaoru
    Nakano, Kazuhisa
    Tanaka, Yoshiya
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [30] Ozone Therapy as a Possible Option in COVID-19 Management
    Gavazza, Alessandra
    Marchegiani, Andrea
    Rossi, Giacomo
    Franzini, Marianno
    Spaterna, Andrea
    Mangiaterra, Sara
    Cerquetella, Matteo
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
12345